Profile of Serum Bile Acids in Noncholestatic Volunteers: Gender-related Differences in Response to Fenofibrate

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2011 Jul 1

PMID 21716269

Citations 25

Authors

J Trottier

P Caron

R J Straka

O Barbier

Affiliations

Soon will be listed here.

Abstract

Fenofibrate belongs to the group of hypolipidemic fibrates that act as activators of the peroxisome proliferator-activated receptor-α (PPARα), which is a regulator of bile acid synthesis, metabolism, and transport. The present study aimed at evaluating the effects of fenofibrate on the circulating bile acid profile in humans. A study population of 200 healthy individuals comprising both genders completed a 3-week intervention with fenofibrate, and 17 bile acid species were measured in serum samples drawn before and after fenofibrate treatment. Fenofibrate caused significant reductions in levels of chenodeoxycholic (CDCA) (-26.4%), ursodeoxycholic (UDCA) (-30.5%), lithocholic (LCA) (-18.4%), deoxycholic (DCA) (-22.3%), and hyodeoxycholic (HDCA) (-19.2%) acids. A gender-related difference was observed in the responses of various bile acids, and the total bile acid concentration was significantly reduced only in men (-18.6%), whereas it remained almost unchanged in women (+0.36%). This difference suggests that fenofibrate would be more efficient at reducing bile acid toxicity in men than in women in cholestatic liver diseases.

Citing Articles

Prediabetes and type 2 diabetes but not obesity are associated with alterations in bile acid related gut microbe-microbe and gut microbe-host community metabolism.

Schlicht K, Pape L, Rohmann N, Knappe C, Epe J, Geisler C Gut Microbes. 2025; 17(1):2474143.

PMID: 40045464 PMC: 11901388. DOI: 10.1080/19490976.2025.2474143.

PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.

Gallucci G, Hayes C, Boyer J, Barbier O, Assis D, Ghonem N Cells. 2024; 13(15.

PMID: 39120326 PMC: 11312002. DOI: 10.3390/cells13151296.

Gender-Specific Bile Acid Profiles in Non-Alcoholic Fatty Liver Disease.

Fitzinger J, Rodriguez-Blanco G, Herrmann M, Borenich A, Stauber R, Aigner E Nutrients. 2024; 16(2).

PMID: 38257143 PMC: 10821077. DOI: 10.3390/nu16020250.

Efficacy of fibrates in the treatment of primary biliary cholangitis: a meta-analysis.

Zhang H, Li S, Feng Y, Zhang Q, Xie B Clin Exp Med. 2022; 23(5):1741-1749.

PMID: 36318376 DOI: 10.1007/s10238-022-00904-2.

Impact of Blueberry Consumption on the Human Fecal Bileacidome: A Pilot Study of Bile Acid Modulation by Freeze-Dried Blueberry.

Gagnon W, Garneau V, Trottier J, Verreault M, Couillard C, Roy D Nutrients. 2022; 14(18).

PMID: 36145234 PMC: 9501813. DOI: 10.3390/nu14183857.

References

Iwasaki S, Akisawa N, Saibara T, Onishi S . Fibrate for treatment of primary biliary cirrhosis. Hepatol Res. 2007; 37 Suppl 3:S515-7. DOI: 10.1111/j.1872-034X.2007.00232.x. View

Levy C, Peter J, Nelson D, Keach J, Petz J, Cabrera R . Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2010; 33(2):235-42. DOI: 10.1111/j.1365-2036.2010.04512.x. View

Tsai M, Ordovas J, Li N, Straka R, Hanson N, Arends V . Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. Mol Genet Metab. 2010; 100(2):118-22. PMC: 3598593. DOI: 10.1016/j.ymgme.2010.03.001. View

Paumgartner G . Pharmacotherapy of cholestatic liver diseases. J Dig Dis. 2010; 11(3):119-25. DOI: 10.1111/j.1751-2980.2010.00427.x. View

Iwasaki S, Ohira H, Nishiguchi S, Zeniya M, Kaneko S, Onji M . The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res. 2008; 38(6):557-64. DOI: 10.1111/j.1872-034X.2007.00305.x. View

Liu Y, Ordovas J, Gao G, Province M, Straka R, Tsai M . The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions. J Hum Genet. 2008; 53(8):709-717. PMC: 3836273. DOI: 10.1007/s10038-008-0302-2. View

Xiang X, Han Y, Neuvonen M, Laitila J, Neuvonen P, Niemi M . High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 878(1):51-60. DOI: 10.1016/j.jchromb.2009.11.019. View

Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K . Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol. 2004; 10(6):894-8. PMC: 4727018. DOI: 10.3748/wjg.v10.i6.894. View

Sharma R, Majer F, Peta V, Wang J, Keaveney R, Kelleher D . Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A). Bioorg Med Chem. 2010; 18(18):6886-95. DOI: 10.1016/j.bmc.2010.07.030. View

10.

Brown J, Plutzky J . Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007; 115(4):518-33. DOI: 10.1161/CIRCULATIONAHA.104.475673. View

11.

Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart J, Staels B . Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem. 2003; 278(35):32852-60. DOI: 10.1074/jbc.M305361200. View

12.

Gnewuch C, Liebisch G, Langmann T, Dieplinger B, Mueller T, Haltmayer M . Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J Gastroenterol. 2009; 15(25):3134-41. PMC: 2705736. DOI: 10.3748/wjg.15.3134. View

13.

Fang H, Strom S, Cai H, Falany C, Kocarek T, Runge-Morris M . Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol Pharmacol. 2005; 67(4):1257-67. DOI: 10.1124/mol.104.005389. View

14.

Monte M, Marin J, Antelo A, Vazquez-Tato J . Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol. 2009; 15(7):804-16. PMC: 2653380. DOI: 10.3748/wjg.15.804. View

15.

Yoon M, Jeong S, Nicol C, Lee H, Han M, Kim J . Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Exp Mol Med. 2003; 34(6):481-8. DOI: 10.1038/emm.2002.67. View

16.

Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M . Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol. 2000; 95(1):326-7. DOI: 10.1111/j.1572-0241.2000.01667.x. View

17.

Smith J, Arnett D, Kelly R, Ordovas J, Sun Y, Hopkins P . The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur J Hum Genet. 2008; 16(5):603-13. PMC: 2546577. DOI: 10.1038/sj.ejhg.5202003. View

18.

Shen J, Arnett D, Parnell L, Peacock J, Lai C, Hixson J . Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Diabetes Care. 2008; 31(5):910-5. PMC: 4615595. DOI: 10.2337/dc07-1687. View

19.

Ye L, Liu S, Wang M, Shao Y, Ding M . High-performance liquid chromatography-tandem mass spectrometry for the analysis of bile acid profiles in serum of women with intrahepatic cholestasis of pregnancy. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 860(1):10-7. DOI: 10.1016/j.jchromb.2007.09.031. View

20.

Hunt M, Yang Y, Eggertsen G, Carneheim C, Gafvels M, Einarsson C . The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. J Biol Chem. 2000; 275(37):28947-53. DOI: 10.1074/jbc.M002782200. View